Immunoglobulin M (IgM), particularly the anti-endotoxin variant, is a type of antibody that plays a crucial role in the immune response, particularly in recognizing and neutralizing bacterial endotoxins. The specific substance you mentioned, which is a disulfide-linked pentameric dimer of human monoclonal antibodies (HA-1A μ-chain and κ-chain), exhibits characteristics typical of IgM, such as a pentameric structure that enhances its ability to bind antigens effectively. This structure allows for a high avidity interaction with pathogens, making it particularly effective in the early stages of immune response. The presence of disulfide bonds contributes to the stability and integrity of the antibody structure. IgM is primarily produced in response to infections and is the first antibody to be produced during an immune response. Its large size and pentameric form enable it to agglutinate pathogens and activate the complement system, facilitating opsonization and clearance of pathogens from the bloodstream. Overall, this specific IgM variant is significant in therapeutic applications, particularly in conditions involving endotoxin exposure.

Immunoglobulin M, anti-endotoxin (human monoclonal HA-1A μ-chain), disulfide with human monoclonal HA-1A κ-chain, pentameric dimer

138661-01-5: Immunoglobulin M (IgM), particularly the anti-endotoxin variant, is a type of antibody that plays a crucial role in the immune response, particularly in recognizing and neutralizing bacterial endotoxins. The specific substance you mentioned, which is a disulfide-linked pentameric dimer of human monoclonal antibodies (HA-1A μ-chain and κ-chain), exhibits characteristics typical of IgM, such as a pentameric structure that enhances its ability to bind antigens effectively. This structure allows for a high avidity interaction with pathogens, making it particularly effective in the early stages of immune response. The presence of disulfide bonds contributes to the stability and integrity of the antibody structure. IgM is primarily produced in response to infections and is the first antibody to be produced during an immune response. Its large size and pentameric form enable it to agglutinate pathogens and activate the complement system, facilitating opsonization and clearance of pathogens from the bloodstream. Overall, this specific IgM variant is significant in therapeutic applications, particularly in conditions involving endotoxin exposure.

Nebacumab (HA-1A), a monoclonal antibody, targets the lipid A component of endotoxin and has potential applications in sepsis research [1] [2].

Nebacumab

Anti-endotoxin human monoclonal antibody; treatment of sepsis

CAS 138661-01-5

Immunoglobulin M, anti-endotoxin (human monoclonal HA-1A μ-chain), disulfide with human monoclonal HA-1A κ-chain, pentameric dimer

Nebacumab

Ref: TM-T77095

Nebacumab

Ref: 3D-CLA1158